AUGUST 30, 2005 - 09:00 ET

FOR IMMEDIATE RELEASE

PHARMENG ANNOUNCES MANUFACTURING CONTRACTS

Toronto, Canada, August 30, 2005 - PharmEng International Inc. (TSXV: PII), a full-service consulting and contract manufacturing company, today announced that its manufacturing subsidiary, Keata, has been given a commitment from two existing customers for combined contracts exceeding $1,600,000 over the ensuing year.

These commitments, from multinational companies, are expected to grow into additional services provided by Keata. Keata was also recently awarded two contracts for the manufacturing, testing and packaging of clinical trial products. With the full integrated support services of PII, the company is in a position to further provide regulatory compliance, technology transfer and commercialization for these products.

"This demonstrates the success of our full service strategy and the confidence of our customers on the ability of Keata to manufacture and deliver quality products", commented Alan Kwong, CEO and Chairman of PharmEng.

About PharmEng International Inc.

PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and certified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. Building on a foundation of over seven years of successful consulting, PharmEng in combination with its wholly owned manufacturing subsidiary, Keata, has evolved into one of Canada's leading pharmaceutical companies. PharmEng's shares trade on the TSX Venture Exchange under the symbol PII. For more information about PharmEng, please visit the Company's website at www.pharmeng.com.

FORWARD LOOKING STATEMENTS

Certain statements in this press release may include "forward-looking" statements which involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of PharmEng to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements use such words as "may", "will", "expect", "anticipate", "project", "believe", "plan", and other similar terminology. The risks and uncertainties are detailed from time to time in reports filed by PharmEng with the securities regulatory authorities in all of the provinces and territories of Canada. New risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the extent to which any factor or combination of factors may cause actual results, performance and achievements of PharmEng to be materially different from those contained in forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction actual results.